368 PATENT ABSTRACTS

Hybrid cell line for production of monoclonal antibody to an antigen found on all normal human T cells. The hybrid is formed by fusing splenocytes from immunized Balb/cJ mice with P3X63Ag8UI myeloma cells. Diagnostic and therapeutic uses of the monoclonal antibody are also disclosed.

4657852

M E T H O D F O R B C E L L T Y P I N G O F T O T A L H U M A N

L Y M P H O C Y T E S A M P L E

Frank C Grumet, Edgar G Engleman assigned to The Board of Trustees of the Leland Stanford Junior University

An HLA-DR typing test based on lympho- cytotoxicity in which a vital dye-labeled total human lymphocyte sample, such as a sample of peripheral blood lymphocytes, is incubated with HLA-DR antisera, a monoclonal antibody against T cells, and complement and the DR type is determined based upon the resultant cyto- toxicity as measured by the fluorescence of B cells surviving the incubation.

according to the present invention, exhibits a higher producibility of immunoglobulin G and immunoglobulin M antibodies, while it induces less or substantially no production of immuno- globulin E antibody, in comparison with conventional-type inactivated virus vaccine; thus. the present vaccine is favorably usable for the prevention and treatment of viral diseases.

4659669

M I C R O B I A L E X P R E S S I O N O F H U M A N I N F L U E N Z A

H E M A G G L U T I N I N P R O T E I N S

Dennis Kleid, Debi P Nayak, Alan R Davis as- signed to Regents of the Univ of California; Genentech Inc

Disclosed herein are methods and means for microbially expressing human influenza hemag- glutinin proteins, useful in the preparation of vaccines, by recombination of DNA gene sequences coding for hemagglutinin protein with microbially operable promoter-operator DNA and transformation of microbial host therewith.

4657894

N E W F A C T O R VII I C O A G U L A N T P O L Y P E P T I D E S

Theodore S Zimmerman, Carol A Fulcher as- signed to Scripps Clinic & Research Foundation

Active factor VIII:C coagulant polypeptides identified by partial amino acid sequences are disclosed.

4659569

P R O C E S S F O R T H E P R O D U C T I O N O F V I R U S

V A C C I N E

Masakazu Mitsuhashi, Shunsaku Koyama, Okayama, Japan assigned to Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo

The present invention relates to a process for the production of virus vaccine, comprising cova- lently attaching virus to saccharide to form a virus-saccharide conjugate, and harvesting the resultant conjugate. The virus vaccine, prepared

4659678

I M M U N O A S S A Y O F A N T I G E N S

Gordon Forrest, Philip R P Salacinski, Kenneth Siddle, lngatestone, United Kingdom assigned to Serono Diagnostics Limited

A method of immunoassay of an antigen in a li- quid sample wherein a complex is formed bet- ween antigen contained in the said sample and two or more antibody reagents, and the said complex is bound to a solid support by non- covalent bonding as defined herein; and the amount of complex becoming bound to the sup- port is determined; the process employing at least one monoclonal antibody reagent. Label- ling methods including radio-active, fluorimetric and enzyme labelling may be used to effect deter- mination of the binding of the complex to the solid support. The solid support may take the form of particles, beads, wall-coatings on the reaction vessel or an insert of large surface area. The method is particularly applicable to the as- say of TSH, CEA, HCG, alphafeto protein, immunoglobulins, viruses, allergens, bacteria, toxins, drugs and vitamins. Use of monoclonal reagents improves the specificity of the process, and also decreases non-specific binding.